Tirzepatide for weight loss in type 1 diabetes
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests a medication called tirzepatide for people with type 1 diabetes who also have overweight or obesity. Tirzepatide may help with weight loss and blood sugar control, and you'll use a continuous glucose monitor throughout the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have type 1 diabetes for at least 1 year, confirmed by a blood test showing low C-peptide (a marker of how much insulin your body still makes).
- Your body mass index (BMI) must be 27 or higher (this is considered overweight or obese).
- You have tried to lose weight through diet before but it didn't work.
- You must already use a continuous glucose monitor (CGM) for at least 2 months and be willing to keep using one for the study.
- You cannot have a recent (within 6 months) diabetic ketoacidosis (DKA) or severe low blood sugar episode, or certain eye problems, or have taken a similar weight-loss drug (GLP-1 agonist) in the last 180 days.
- You must be free of serious mental health conditions (like depression or suicidal thoughts) in the recent past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called tirzepatide, given at carefully adjusted doses, to help people with obesity lose weight while reducing unwanted side effects. Tirzepatide is a newer injectable medicine that helps control appetite and blood sugar.
This study tests a weekly injection called tirzepatide in people with type 1 diabetes who are overweight or have obesity. The goal is to see if it helps with blood sugar control and weight loss when added to insulin therapy.
This study tests a medicine called tirzepatide to see if it helps people with overweight or obesity lose weight, whether or not they also have type 2 diabetes. Tirzepatide is given as an injection and works on hormones that control appetite.
This trial tests if tirzepatide is more effective than standard obesity treatments for adults who have a BMI between 30 and 35 and one weight-related health condition, but do not have diabetes. The goal is to help you lose weight.
This study tests a weekly injection called tirzepatide to help people with obesity lose weight. It will be done at Hospital de Clínicas in Paraguay and lasts about 12 months.
This study tests a medication called tirzepatide (a once-weekly injection) to help teenagers with obesity and related health conditions lose weight. It aims to see if the drug is safe and effective for this age group.
Hear when a new Type1diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.